SMARCA4-deficient Malignant Tumors clinical trials at UCSF
1 research study open to eligible people
SMARCA4-deficient malignant tumors are cancers missing a key gene that helps control cell growth. UCSF is studying how two immunotherapy drugs, nivolumab and ipilimumab, might treat these tumors in children and young adults. These trials aim to find new ways to manage these challenging cancers.
Showing trials for
Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
open to eligible people ages 6 months to 40 years
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
San Francisco, California and other locations
Our lead scientists for SMARCA4-deficient Malignant Tumors research studies include Alyssa Reddy.
Last updated: